AppLovin Stock Gets A Needham Upgrade – Why Does The Firm See A 33% Upside Potential For The Stock?
Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.
uniQure Stock Tumbled 55% Today: What’s The FDA Angle?
The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.
